Analyst Price Targets — MCRB
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 7, 2024 5:10 am | Keay Nakae | Chardan Capital | $1.25 | $0.85 | TheFly | Seres Therapeutics price target lowered to $1.25 from $6 at Chardan |
Latest News for MCRB
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration
Pharmacologic data highlight durable GI microbiome modulation, with improvement in epithelial barrier integrity, following SER-155 administration
CAMBRIDGE, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today announced that it will present at the 2026 CARB-X Investor Day on April 16, 2026, which precedes the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global conference in Munich, Germany.
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026
Seres Therapeutics, Inc. (MCRB) Discusses Leadership Transition, Strategic Direction and Microbiome Therapeutics Platform Prepared Remarks Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MCRB.
U.S. House Trading
No House trades found for MCRB.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.